Drug boosts survival of relapsed multiple myeloma

Adding the drug lenalidomide, a less-toxic relative of the drug thalidomide, to standard dexamethasone therapy can improve survival in patients with relapsed or hard-to-treat multiple myeloma (cancer of the blood). More

Comments

Popular posts from this blog

WIPO Pearl - Recap

Databases on the FDA Website

Zotero - Next Generation Research Tool